HER2 Negative Metastatic Breast Cancer Pipeline Insight and Clinical Trial Phases Report | 50+ Companies and 50+ Drugs

DelveInsight's, "HER2 Negative Metastatic Breast Cancer Pipeline Insight, 2023" report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Her2 Negative Metastatic Breast Cancer pipeline landscape. It covers the HER2 Negative Metastatic Breast Cancer pipeline drug profiles, including HER2 Negative Metastatic Breast Cancer clinical trial and nonclinical stage products. It also covers the HER2 Negative Metastatic Breast Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key takeaways from the HER2 Negative Metastatic Breast Cancer Pipeline Report

• DelveInsight's HER2 Negative Metastatic Breast Cancer Pipeline analysis depicts a robust space with 50+ active players working to develop 50+ pipeline treatment therapies.

• The leading HER2 Negative Metastatic Breast Cancer Companies are working to develop drug candidates to improve HER2 Negative Metastatic Breast Cancer treatment landscape includes BeiGene, Context Therapeutics, Astex Pharmaceuticals, Eisai Inc., AstraZeneca, Dantari, Inc., and others.

• Promising HER2 Negative Metastatic Breast Cancer Pipeline Therapies in various stages of development include MM-121, Paclitaxel, BGB-290, AZD9833, Fulvestrant, Exemestane, Eribulin, Cyclophosphamide, Docetaxel, Dato-DXd, Capecitabine, and others.

• The HER2 Negative Metastatic Breast Cancer Companies and academics are working to assess challenges and seek opportunities that could influence Her2 Negative Metastatic Breast Cancer R&D. The HER2 Negative Metastatic Breast Cancer pipeline therapies under development are focused on novel approaches to treat/improve Her2 Negative Metastatic Breast Cancer.

Explore latest breakthroughs of HER2 Negative Metastatic Breast Cancer Treatment Landscape and HER2 Negative Metastatic Breast Cancer Pipeline Outlook @ https://www.delveinsight.com/report-store/her2-negative-metastatic-breast-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

HER2 Negative Metastatic Breast Cancer Overview

Breast cancer is the world's most common disease in women, and is also a major factor that leads to death. It is reported that 5% of patients with breast cancer have distant metastasis at a diagnosis, and 30% of patients with early cancer subsequently experience the distant metastasis. Metastatic breast cancer cannot be completely cured; however, significant improvement in the survival period was observed consistent with the emergence of novel therapy. The purpose of the treatment for metastatic breast cancer is to prolong the survival period and improve the cancer patients' quality of life (QOL) by managing cancer-related symptoms. To that end, not the same strategy for all patients but individual approach for each patient should be used. When a breast cancer is HER2-negative, it means that the cancerous cells do not contain high levels of the protein HER2. There are many treatment options available for this type of breast cancer, but the outlook can vary.

Recent Developmental Activities in the HER2 Negative Metastatic Breast Cancer Treatment Landscape

• Pamiparib is a selective small molecule inhibitor of poly ADP-ribose polymerase 1 (PARP1) and PARP2 enzymes that is being evaluated as a potential monotherapy and in combinations for the treatment of various solid tumors. It is believed that pamiparib has the potential to be differentiated from other PARP inhibitors because of its brain penetration, greater selectivity, strong DNA-trapping activity, and good oral bioavailability demonstrated in preclinical models. . Currently, the drug is being developed in the Phase II stage of clinical trial evaluation for the treatment of Her2 Negative Metastatic Breast Cancers.

• ONA-XR is an investigational medicine that prevents progesterone signaling by blocking the interaction between progesterone and its binding partner, progesterone receptor. Onapristone is the only known full PR antagonist. Currently, there are no approved therapies that selectively target progesterone receptor positive (PR+) cancers. Preclinical and clinical data suggest that onapristone extended release (ONA-XR) has anticancer activity by inhibiting PR binding to chromatin, down regulating cancer stem cell mobilization and blocking immune evasion. ONA-XR is currently being evaluated in four Phase 2 trials and two Phase 0 biomarker pharmacodynamic trials in women with primary or metastatic breast, ovarian, and endometrial cancers. . Currently, the drug is being developed in the Phase II stage of clinical trial evaluation for the treatment of Her2 Negative Metastatic Breast Cancers.

Discover more about the report offerings HER2 Negative Metastatic Breast Cancer Emerging Therapies @ https://www.delveinsight.com/sample-request/her2-negative-metastatic-breast-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

HER2 Negative Metastatic Breast Cancer Emerging Drugs Profile
• Pamiparib: BeiGene
• Onapristone: Context Therapeutics

HER2 Negative Metastatic Breast Cancer Therapeutics Assessment
There are approx. 50+ key companies which are developing the therapies for Her2 Negative Metastatic Breast Cancer. The companies which have their Her2 Negative Metastatic Breast Cancer drug candidates in the most advanced stage, i.e. phase II include, BeiGene.

Learn more about the novel and emerging HER2 Negative Metastatic Breast Cancer pipeline therapies @ https://www.delveinsight.com/report-store/her2-negative-metastatic-breast-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the HER2 Negative Metastatic Breast Cancer Pipeline Report

• Coverage- Global

• HER2 Negative Metastatic Breast Cancer Companies- BeiGene, Context Therapeutics, Astex Pharmaceuticals, Eisai Inc., AstraZeneca, Dantari, Inc., and others.

• HER2 Negative Metastatic Breast Cancer Pipeline Therapies- MM-121, Paclitaxel, BGB-290, AZD9833, Fulvestrant, Exemestane, Eribulin, Cyclophosphamide, Docetaxel, Dato-DXd, Capecitabine, and others.

• HER2 Negative Metastatic Breast Cancer Segmentation: Phases, Molecule Type, Mechanism of Action, Route of Administration, Product Type

Table of Content
1. Introduction
2. Her2 Negative Metastatic Breast Cancer Executive Summary
3. Her2 Negative Metastatic Breast Cancer: Overview
4. Her2 Negative Metastatic Breast Cancer Pipeline Therapeutics
5. Her2 Negative Metastatic Breast Cancer Therapeutic Assessment
6. Her2 Negative Metastatic Breast Cancer- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Drug name : Company name
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Pamiparib: BeiGene
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. Drug name : Company name
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Her2 Negative Metastatic Breast Cancer Key Companies
21. Her2 Negative Metastatic Breast Cancer Key Products
22. Her2 Negative Metastatic Breast Cancer- Unmet Needs
23. Her2 Negative Metastatic Breast Cancer- Market Drivers and Barriers
24. Her2 Negative Metastatic Breast Cancer- Future Perspectives and Conclusion
25. Her2 Negative Metastatic Breast Cancer Analyst Views
26. Her2 Negative Metastatic Breast Cancer Key Companies
27. Appendix

For further information on the HER2 Negative Metastatic Breast Cancer Pipeline report, reach out HER2 Negative Metastatic Breast Cancer Ongoing Clinical Trials @ https://www.delveinsight.com/sample-request/her2-negative-metastatic-breast-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

For Healthcare Market Research Reports and Healthcare Research Reports, just visit here @ https://www.delveinsight.com/?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

This release was published on openPR.